Heme oxygenase (HO) is the rate-limiting enzyme in the heme catabolic pathway in which heme is converted into equimolar quantities of carbon monoxide, ferrous iron (Fe 2 + ), and biliverdin. 8 Biliverdin is then further catalyzed by biliverdin reductase to form bilirubin. Because the products of this pathway are potentially toxic, expression of HO is well regulated within the body. Despite the need for tight control, basal expression of the HO-2 isozyme is constitutive and ubiquitous throughout the body.
OVERVIEW
Heme oxygenase (HO) is the rate-limiting enzyme in the heme catabolic pathway in which heme is converted into equimolar quantities of carbon monoxide, ferrous iron (Fe 2 + ), and biliverdin. 8 Biliverdin is then further catalyzed by biliverdin reductase to form bilirubin. Because the products of this pathway are potentially toxic, expression of HO is well regulated within the body. Despite the need for tight control, basal expression of the HO-2 isozyme is constitutive and ubiquitous throughout the body.
However, induction of the HO-1 isozyme occurs in response to a variety of stimuli. Here we review the in vivo transcription patterns of HO-1 and its induction in response to a variety of chemical inducers. High throughput live cell assays were established and evaluated. Results from the cell assays were then related to spatiotemporal analyses of transcriptional regulation using a living transgenic (Tg) reporter mouse model. The combination of rapid live cell assays and whole-body analysis in animal models facilitated the rapid assessment of HO-1 transcription patterns in response to a variety of stimuli including potential therapeutics for pathologic jaundice.
Whole-body images revealed increase in HO-1 transcription in Tg mice after treatment with heme and the heavy metal cadmium. Intravenous (IV) injections of cadmium resulted in expression patterns that differed in tempo and location from those observed in mice treated with intraperitoneal (IP) injections. Metalloporphyrins (Mps), competitive inhibitors of HO, were also evaluated in these assays to reveal the effects of these potential chemotherapeutic agents that reduce bilirubin production. Using both whole-body imaging of gene expression and ex vivo assays for HO-1 protein, increased levels of HO-1 transcription were observed following administration of some selected Mps. We observed that zinc bis glycol porphyrin (ZnBG), a potent inhibitor of the HO, did not alter HO-1 transcription patterns in either cells or Tg mice. Further, in vivo evaluation of transcriptional regulation using rapid whole-body assays revealed the dynamics of gene expression and the different patterns of transcriptional regulation in response to varied stimuli.
HEME OXYGENASE AS A KEY ENZYME IN HEME CATABOLISM
There are three HO isoenzymes identified to date. The two most well studied HO isoenzymes are HO-1 and HO-2. HO-1 is the inducible isoform that is activated by a wide variety of internal and external stimuli, whereas HO-2 is constitutive and relatively insensitive to exogenous stimulation. These isozymes have important, yet different, roles in normal physiology and development pertaining to the catabolism of heme from senescing red blood cells as well as from the turnover of other hemoproteins. 6 Because fluctuations in heme levels can be sudden, a rapid cellular response is required that may include increasing HO enzyme levels, through regulation at the level of HO-1 transcription.
Gene fusions composed of specific promoters and bioluminescent reporter genes can be used to assess gene expression patterns using whole -body imaging in living animal models. A transgenic mouse model was developed using the regulatory elements of the heme oxygenase promoter to drive luciferase as the reporter gene. In these transgenic mice, heme oxygenase ( HO ) -1 expression was apparent in neuronal tissues of neonates but not adults as measured by whole -body imaging, and in adults transcription of the reporter gene was inducible by known inducers of HO -1 transcription. Whole -body imaging of luciferase activity was then used to evaluate the effects of metalloporphyrins ( Mps ) on the transcription of the reporter gene. Some of the Mps, which are potent inhibitors of HO activity, did not activate the reporter gene above background. These Mps are ideally suited as chemotherapeutics that may target bilirubin production rates by inhibiting HO activity, but not result in a net increase in output from the HO gene. In contrast, known inducers of HO transcription did increase luciferase activity as did some of the other Mps that have been examined. Using whole -body in vivo transcriptional assays may facilitate rapid screening of potential therapeutic compounds for both desired and untoward effects. Journal of Perinatology 2001; 21:S119 -S124.
Based on ex vivo assays using Northern blot hybridization, HO-1 message levels were found to be elevated in a tissuespecific manner, which has been further substantiated by detecting elevated levels of HO-1 protein and HO activity. 4 These observations indicated that the examination of the profiles of HO-1 gene expression in living systems, where the responding cells are in the context of intact organ systems, was essential. 13, 14 Therefore, we developed an in vivo assay for HO-1 transcription that would permit real-time and noninvasive determinations of transcriptional activation in a variety of organs simultaneously. For this purpose we applied the method of whole-body bioluminescence imaging using low light imaging systems to detect expression of reporter genes that encode light producing enzymes. 13, 14 This imaging strategy is based on the observation that light penetrates tissues at a low yet detectable level, and on the fact that reporter genes that encode light-producing enzymes can be engineered into biologic systems as functional in vivo reporter genes. 2, 3 The efficiency of light transmission through the relatively opaque tissue of mammals is dependent on the color of light produced. Since shorter wavelengths of light are absorbed by hemoglobin, blue light penetrates poorly and red light penetrates more efficiently. Light scattering also reduces optical signals as they pass through tissues. The net reduction of bioluminescent signal has been estimated from in vitro studies to be approximately 10-fold for every centimeter of tissue traversed (such estimations will vary with tissue type). 1 Even weak internal signals from deep sources such as the liver, lung, and intestine are transmitted through the relatively opaque tissues and can be detected externally, despite the losses due to absorbance and scattering. 2, 12 The sensitivity of the in vivo measurements are approximately that same as those obtained using ex vivo luciferase (luc) activity measurements; the reporter detection limit in the liver was 35 pg of luc enzyme per gram of liver tissue, and one in a million transduced liver cells. 5 
HO-1 EXPRESSION PATTERNS IN CELL CULTURE ASSAYS AS CORRELATES OF IN VIVO EXPRESSION PATTERNS
To establish the HO-1 model, the HO-1 transcriptional regulatory unit and fractions of this promoter were fused to the coding sequence of a modified luc gene originally derived from the North American firefly. 13 These constructs were then used to generate stable cell lines that express luc in response to stimuli that are known to induce expression of HO-1. 13 The effects of various inducers of HO-1 transcription were evaluated using a mouse fibroblast cell line (NIH 3T3) transfected with the full-length and truncated HO-1 promoters. The full-length HO-1 promoter contained the two described distal enhancer elements (DE-1 and DE-2) and a proximal enhancer in addition to the basal promoter, whereas the truncated HO-1 promoter contained only the basal promoter element and the proximal enhancer region. When basal levels of luc expression were determined in cultures of stable lines, cells with the truncated promoter expressed only a fraction of that of cells containing the full-length promoter. Therefore, the two distal enhancer elements in the 5 0 flanking region of HO-1 gene appeared to be required to maintain normal basal levels of HO-1 expression. 13 Transcriptional activation of the full-length HO-1 promoter was initially observed at 4 h after treatment with the known inducers CdCl 2 or heme. Peak expression of the reporter gene was observed at 10 h post treatment. Following exposure to 5 M CdCl 2 , expression was greater than that of untreated cells at peak induction, and expression in the absence of the two distal enhancers expression increased only moderately (Figure 1 ). After treatment with 20 M heme, expression from the truncated promoter was reduced, while that in cells containing the full- 4 cells in 300 l of growth medium containing luciferin. Cells were imaged using the ICCD camera with 2-minute integration times and signal from each well was quantified using image -processing capabilities of the Argus 20 (Hamamatsu City, Japan ).
length promoter increased three-fold. Both treatment with CdCl 2 and heme resulted in increased expression from the full-length HO-1 promoter in a dose-and time-dependent manner. Once the promoter constructs were characterized using these stable cell lines, the fusion containing the full-length promoter was used to create a Tg mouse line that would serve as a reporter mouse for HO-1 transcriptional regulation. 14 
EXPRESSION PATTERNS IN YOUNG AND ADULT
HO-1-luc TG MICE HO-1 is widely expressed in tissues of neonatal HO-1-luc Tg mice where basal levels of reporter gene expression were detectable over the entire body. The signal intensity, however, was greatest over the cranium of the HO-1-luc positive pups than other regions of the body (Figure 2 ). This expression pattern was observed and reproducible in each of the pups, but the intensity appeared to vary slightly from mouse to mouse. This pattern of expression of HO-1 in the brain of neonates is consistent with observations made by immunocytochemistry staining for HO-1 protein.
In adult mice, high basal levels of HO-1 expression were detected in the testes of male homozygous HO-1-luc Tg mice and confirmed by Western blot analyses. 13 Consistent with the in vivo luc imaging data, higher levels of HO-1 protein were apparent in the testes than in the liver as analyzed by Western blots.
14 In the liver, ex vivo Luc activity was near background levels and also apparent in the in vivo assay. The in vivo Luc imaging data are consistent with previous observations of low basal levels of HO-1 in many tissues including the liver. 7 
INDUCIBLE EXPRESSION OF THE HO-1 PROMOTER IN THE HOMOZYGOUS HO-1-luc TG MICE
In our studies, CdCl 2 was also used to confirm the patterns of transcription in the HO-luc Tg mouse line. 13, 14 Whole-body images were obtained at several time points after intramuscular injections of CdCl 2 into the left thighs of Tg mice. The levels of HO-1 protein, expressed from the native HO-1 locus, have been assessed by Western blot analyses. 13 A significant signal was detected in each treated thigh, but not in the contralateral control thighs, which were mock treated and did not receive the heavy metal inducer. In these studies, reporter gene expression peaked at 9 h post induction, and decreases were observed at 24 h post induction. To verify that the reporter gene expression mirrored expression of the HO-1 protein from the native HO-1 gene, Western blot analyses were used to determine that HO-1 protein levels were also elevated in the treated thigh, but not in the control thigh. These studies validated the reporter mouse model of HO-1 transcription revealing that the patterns of reporter gene activation indicated transcriptional activation of the HO-1 gene.
To follow on the induction patterns observed with intramuscular injections, CdCl 2 (at 10 mol/kg) was administered through IV and IP injections. 13 These injections resulted in different patterns of increased luc expression in internal organs. Expression of HO-1, following IV administration of CdCl 2 , peaked at 6 h with a range of 10-to 150-fold increase, while maximal induction following IP injection appeared at 12 h with a range of 15-to 50-fold increase over levels of expression in untreated mice. Signals from animals receiving IV injections of CdCl 2 appeared to originate primarily from the liver, and decrease to background within 48 h. In contrast, IP treated mice displayed increased reporter gene expression in the liver as well as from a second site in the lower abdominal region. Following laparotomy, this second site was determined to be the prepucial gland in the male HO-luc mice. As in the IV treated animals, signals from the liver of IP treated animals returned to background within 48 h while those from the lower abdominal area were still detectable after 96 h. and litters screened for luc activity using an ICCD camera. Pups from one of homozygous females (A) and from one of heterozygous females (B) are shown. In both sets of animals, expression of luc from the CNS is detectable; this differs from adult mice where HO -1 directed expression of luc is not detectable in the CNS.
COMPETITIVE INHIBITORS OF HO-1 ACTIVITY AND UNTOWARD EFFECTS ON TRANSCRIPTION
As the rate-limiting step in the production of bilirubin, HO enzymes have been identified as key molecular target for therapies directed at preventing hyperbilirubinemia in newborn infants. Various heme analogs and synthetic and natural Mps are competitive inhibitors of HO enzyme activity, and these have been evaluated for the purpose of preventing neonatal hyperbilirubinemia by reducing bilirubin production in neonates. 9, 10 Some Mps have been shown, however, to increase expression of HO-1 at the level of transcription, and these increases in HO-1 production may offset the clinical utility of Mps. The effects of Mps on the activity of HO isozymes and on HO-1 gene expression have been examined. 11, 13, 14 Applying our HO-luc Tg mouse model allowed access to in vivo data and this real-time information about HO-1 transcription has provided valuable insight into the mechanisms of action of Mps. Assessing gene expression patterns in living Tg animal models will provide additional information that could facilitate the selection of safe and efficacious Mps for the prevention of neonatal hyperbilirubinemia.
The ideal Mp for this application would be a potent HO enzyme inhibitor that is orally absorbable without significant phototoxic effects and has negligible effects on HO-1 transcription. Twelve Mps, each with one of three central metals (chromium, Cr; tin, Sn; or zinc, Zn) and one of the following porphyrin ring substituents: deutero-(DP), meso-(MP), bis glycol-(BG), or proto-(PP) porphyrin, were evaluated at concentrations ranging from 0 to 20 M as described above and summarized in Table 1 . 13 All Mps at 20 M decreased expression from the truncated promoter; however, for the cells containing the full-length promoter several of the Mps induced reporter gene transcription. ZnMP appeared to be the strongest inducer with a two-fold increase over controls. ZnDP, ZnPP, SnMP, or CrPP induced expression with a range of slightly greater than one-to three-fold. Treatment with SnBG, SnPP, or CrMP slightly increased expression, whereas, ZnBG, SnDP, CrBG, or CrDP lowered HO-1 expression compared to matched, but untreated controls. In this model, heme increased expression of cells containing the full-length promoter by three-fold over control cells.
SnMP, ZnPP, and ZnBG, were then selected for further evaluation since SnMP has been in clinical trials, ZnPP is a naturally occurring Mp, and ZnBG has been shown to be orally bioavailable, a good inhibitor of HO enzymatic activity and a poor inducer of HO-1 transcription. The effects of Mps on transcription in the stable HOluc murine cell lines containing the full and truncated HO-luc promoters was assessed at concentrations ranging from 0 to 20 M. The temporal induction patterns following treatment with SnMP and ZnPP were similar to those observed after treatment with heme. The effects were also time-and dose-dependent achieving peak levels within 10 h after treatment. Compared to the nearly three-fold induction by SnMP and ZnPP, the selected Mp, ZnBG, did not increase expression in either reporter cell line even at the highest concentration. 13 The three selected Mps were then evaluated in adult female mice. ZnPP increased HO-1 expression 3-to 10-fold after IV injection, in these animals signal returned to near background levels by 24 h. In contrast, HO-1 expression rose only 1-to 2-fold following IP injection, but remained elevated throughout the study period. Similarly, SnMP increased HO-1 expression 3-to 11-fold after IV injection and only 3-fold after IP injection with detectable signals above background persisting for over 96 h. There were no detectable changes in ZnBG-treated animals. The signals observed after treatment with Mps appeared to be more random and over a greater area of the body in comparison to those in animals that received CdCl 2 through IP injections. Elevated signals were determined to originate from the liver, spleen, and several other tissues in the peritoneal cavity.
SUMMARY AND DISCUSSION
Currently, preclinical evaluation of chemotherapeutic compounds is largely based on animal studies that lack access to real-time in vivo information pertaining to drug effects on the target cells and molecules or to untoward effects, such as affecting unintentional sites. Traditionally, selection of Mps for the prevention of neonatal jaundice would be based on the potency of inhibiting HO enzymatic activity, pharmacologic parameters, and phototoxicity. However, several Mps that meet the considerations above have also been shown to increase HO-1 gene expression, which may offset their therapeutic effect in controlling bilirubin production. In the absence of rigorous examination of each of these parameters, including transcriptional effects of Mps on the HO-1 gene, less desirable compounds could be selected for clinical trials, and the results of these trials could be confounded or unsuccessful.
The luc assay is a transcriptional reporter indicative of promoter activity; this comprises only a subset of the overall regulatory mechanism. HO-1 protein accumulation, although related to transcriptional activity, is likely subject to additional regulation because HO-1 is a general stress response protein responding to a variety of physiological stimuli, and carbon monoxide is produced by the HO reaction. Enzyme levels are likely to be tightly regulated to prevent unnecessary production of the potentially toxic heme catabolic products. In addition, ex vivo assays are necessarily limited by the inability to obtain fine temporal analyses, and time points demonstrating different HO-1 protein levels may not have been assayed.
Unlike the cell culture assays, the effects of Mps on HO expression in mice are influenced by bioavailability, stability in complex media, and other biologic parameters; therefore, we evaluated the effects of selected Mps on HO-1 expression in vivo using the HO-luc Tg mouse model. ZnBG has been shown to be a potent inhibitor of HO enzymatic activity. This compound is orally absorbable, and in this study, did not significantly increase transcription from the HO-1 promoter in cells. These characteristics of ZnBG are consistent with it being an ideal compound to inhibit HO activity in vivo and it was thus selected for further evaluation. The in vivo experiments demonstrated that SnMP and ZnPP increased expression of the reporter gene after a single treatment, and induction following SnMP treatment appeared to persist beyond that of ZnPP. The increased reporter gene signal following IV treatment of mice with ZnPP returned to background levels quickly suggesting that ZnPP was quickly transported to the liver and removed and ZnPP injected IP remained in the peritoneal cavity for an extended period of time leading to increased local effects. ZnBG, as expected from the correlative cell-based assay, did not increase expression of the reporter gene above background levels. Coupled with the previous studies on ZnBG, these data indicate that this Mp may be well suited for the treatment of neonatal hyperbilirubinemia. Extension of these studies to evaluation of differential HO-1 expression in neonatal Tg mice will be important for understanding the development of neonatal jaundice and the selection of the optimal treatment of this physiologic imbalance.
Noninvasive assays for gene expression permit assessment of the overall patterns of gene expression and can be used to direct subsequent ex vivo assays such as Northern or Western analyses. The data obtained through imaging provides both temporal as well as spatial information, which offers significant advantages over conventional methods. The ability to monitor gene expression patterns in single groups of animals over time increases the statistical significance and enhances the predictability of the animal model.
Use of high-throughput whole-body assays, such as the one described here, are essential for thorough in vivo analyses in that the overall expression patterns can be assessed in all tissues that have significant reporter gene signals. The ability to directly monitor biologic processes in living animal models of human biology and disease will greatly enhance the utility of animal models and can be used to identify new targets for therapy, and accelerate the development of novel therapeutic strategies.
In vivo detection of light from photoprotein reporters can be used to quantify spatial and temporal fluctuations in gene expression from living Tg animals. The use of such dynamic assays to measure and image transgene expression will result in increased information under both physiological and pathophysiological conditions. Rapid screening and analysis of the transgenic lines will facilitate the process of generating Tg animals and selecting the most informative lines. Animal models with molecular indicator lights, such as luciferase, which can be used to predict changes in gene expression patterns, represent a powerful tool for multiparameter analyses of gene expression. With the development of target-directed therapies that are intended to alter disease-related gene expression, it is necessary to refine Tg models to accelerate the preclinical stage of drug development. The effects of potentially useful therapeutic compounds on expression of specific genes can be evaluated in the entire body and over time. The information from living animals more accurately represents responses to therapies than that from conventional biochemical assays performed in vitro and ex vivo. This high-throughput broadly applicable approach can generally be used to refine animal models such that we can rapidly obtain more information about potential therapies and improve the predictive value of these model systems.
